Charlotte, N.C – Bourne Partners (“Bourne”), a leading financial services firm specializing in the pharma, pharma services, OTC, and consumer health sectors announced the appointment of Dr. Martin Zentgraf, as a Senior Advisor to the firm.

Based in Hamburg, Germany, Martin has 35 years of leadership in the European pharma and medtech industry, including 6 years as chairman of the Federal Association of the Pharmaceutical Industry and more than 10 years as a Board Member.  Most recently, Martin was the Managing Director and Speaker of the Board of management of Desitin Arzneimittel GmbH, a European specialty pharmaceutical company focused on the CNS and rare diseases markets.  While at Desitin he was responsible generally for the whole company with a focus on strategic direction, M&A and other business development initiatives and for the commercial organization.

Dr. Zentgraf began his career at Byk Gulden (now Takeda) as a Product Manager and was responsible for various successful licensing projects and launches. Early in his career, Martin changed to GSK as Group Product Manager, where he was responsible for multiple successful product launches. Martin was also active in the medical device business as the Business Unit Director at Pfrimmer-Viggo (BOC OHMEDA) and Head of the Medical Division at REHAU. Martin received an MD from the University of Münster and earned a Doctor title. He is fluent in German, Spanish, and English.

“Martin is a long-time friend and industry colleague of our firm. He brings a great deal of knowledge and experience that will be invaluable to expanding our European presence,” said Banks Bourne, Founder and CEO of Bourne Partners. “Martin’s contributions will help us as we continue to carry out our company’s growth initiatives, expanding our M&A advisory business and pipeline, and broadening the variety of services that we provide. We are looking forward to working together to ensure that the business continues to prosper.”

“I’ve known Banks and the team at Bourne Partners for several decades and I am looking forward to the opportunity to collaborate with the firm. I always enjoyed working with Banks, Jeremy and their team because of their contagious energy and optimism, combined with customer focused hard and successful work. The company’s record and reputation speak for themselves, and I am eager to see what more we can do together”, said Martin Zentgraf.

Jeremy Johnson, Managing Director commented, “We’ve known Martin for a long time. He (while at Desitin) was one of my first clients when I joined Bourne Partners in 2006. Since then, we’ve worked together on many successful mandates.  I have tremendous respect for Martin and am excited to have him join the Bourne Partners team.  Martin is extremely well respected and well connected throughout the German and European pharmaceutical community. Martin will be an invaluable team member as Bourne Partners expands its activities and local presence in Europe.”

About Bourne Partners

Bourne Partners is a financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors. Located in Charlotte, North Carolina, the company offers investment banking and advisory services.  Through Bourne Partners Strategic Capital (“BPSC”), Bourne invests and manages private equity investments in companies within the firm’s core focus areas. As owners and operators with over 20 years of experience, Bourne Partners strives to enrich the lives and improve the health and well-being of their partners and patients across the globe by facilitating the efficient movement of capital through the global healthcare sector. For more information, please visit www.bourne-partners.com.